Abacus Bioscience
Abacus Bioscience: Pioneering immunotherapies for chronic diseases and cancers since 2017.
Founded
2017Abacus Bioscience: Pioneering immunotherapies for chronic diseases and cancers since 2017.
Abacus Bioscience, founded in 2017 and headquartered in Seattle, Washington, is dedicated to developing innovative immunotherapies for chronic infectious diseases and cancers. The company's core mission is to extend the immunotherapy frontier by creating first-in-class active immunotherapies that overcome immune tolerance. Abacus Bioscience offers a versatile platform capable of integrating with various cancer and viral antigens, aiming to provide effective treatments for a wide range of chronic conditions.
Notable figures affiliated with Abacus Bioscience include leading scientists and industry experts in immunotherapy and biotechnology. The company has attracted significant investment from prominent venture capital firms specializing in healthcare innovation. Key achievements include the development of experimental drugs with structures predicted by advanced technologies like AlphaFold. Abacus Bioscience's impact lies in its potential to revolutionize the treatment landscape for chronic infections and cancers, offering hope to patients worldwide.
Companies similar to Abacus Bioscience include Therabiol, SAB Biotherapeutics, Asher Bio and 3T Biosciences.
Abacus Bioscience was founded in 2017.
Abacus Bioscience's headquarters is located in Seattle, WA, US.
Abacus Bioscience's most recent funding round was for $4.4M (USD) in February 2023.
As of Feb 1, 2023, Abacus Bioscience has disclosed funding of $4.4M (USD). Undisclosed round amounts are excluded.
Abacus Bioscience has 2 employees as of Feb 5, 2024.
3T Biosciences
3tbiosciences.com
